TY - JOUR T1 - Predictors of characteristics associated with negative first SARS-CoV-2 PCR testing despite final diagnosis of COVID-19, and association with treatment and outcomes. The COVID-19 RT-PCR Study JF - medRxiv DO - 10.1101/2020.09.14.20194001 SP - 2020.09.14.20194001 AU - Jean-Baptiste Lascarrou AU - Gwenhael Colin AU - Aurélie Le Thuaut AU - Nicolas Serck AU - Mickael Ohana AU - Bertrand Sauneuf AU - Guillaume Geri AU - Jean-Baptiste Mesland AU - Gaetane Ribeyre AU - Claire Hussenet AU - Anne Sophie Boureau AU - Thomas Gille Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/21/2020.09.14.20194001.abstract N2 - Background Reverse transcriptase-polymerase chain reaction (RT-PCR) testing is an important tool for the diagnosis of coronavirus disease 2019 (COVID-19). However, performance concerns have recently emerged, especially about its sensitivity.. We hypothesized that clinical, biological and radiological characteristics of patients with false negative first RT-PCR testing, despite final diagnosis of COVID-19, might differ from patients with positive first RT-PCR.Methods Case – control, multicenter study in which COVID-19 patients with negative first RT-PCR testing were matched to patients with positive first RT-PCR on age, gender and initial admission unit (ward or intensive care).Results Between March 30, and June 22, 2020, 80 cases and 80 controls were included. Neither proportion of death at hospital discharge, nor duration of hospital length stay differed between “case” and “control” patients (P = 0.80 and P = 0.54, respectively). In multivariate analysis, headache (adjusted OR: 0.07 [0.01; 0.49]; P = 0.007) and fatigue/malaise (aOR: 0.16 [0.03; 0.81]; P = 0.027) were associated with lower risk of false negative, whereas platelets > 207.103.mm−3 (aOR: 3.81 [1.10; 13.16]; P = 0.034) and CRP > 79.8 mg.L−1 (aOR: 4.00 [1.21; 13.19]; P = 0.023) were associated with higher risk of false negative.Interpretation Patients with suspected COVID-19 and higher inflammatory biological signs expected higher risk of false negative RT-PCR testing. Strategy of serial RT-PCR testings must be rigorously evaluated before adoption by clinicians.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the appropriate ethics committees (For France: Comite d ethique de la Societe de Reanimation de Langue Francaise, #20-26; and for Belgium: Comite d ethique 045 Clinique Saint Pierre) which waived consent according to data collected.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request to corresponding author with protocol approved by IRB. ER -